Okay, let's tackle this question. The user is asking about the metabolic abnormality associated with long-term spironolactone use. First, I need to recall what spironolactone does. It's a potassium-sparing diuretic, right? So it works by antagonizing aldosterone in the distal convoluted tubule. Aldosterone normally promotes sodium reabsorption and potassium excretion. By blocking it, spironolactone causes sodium excretion and potassium retention.

Wait, the question is about a metabolic abnormality. Common side effects of spironolactone include hyperkalemia because it's potassium-sparing. That's a big one. But maybe there's another one? Let me think. Hyperkalemia is definitely a key point here. But sometimes other electrolyte imbalances can occur. For example, hyperchloremia because it's a diuretic that can cause chloride retention. Wait, no, maybe not. Let me check. Spironolactone's main effect is on potassium. Also, since it's a diuretic, it might cause some fluid retention, but the primary issue is hyperkalemia.

Now, looking at the possible options, even though they aren't listed here, the correct answer is likely hyperkalemia. The other options might include things like hypokalemia (which would be incorrect), hyponatremia (maybe from SIADH?), but spironolactone is more about potassium. Also, metabolic alkalosis or acidosis? Spironolactone is a diuretic that can cause metabolic acidosis because of potassium retention and hydrogen ion loss. Wait, maybe that's another point. But the primary metabolic abnormality is hyperkalemia.

So the core concept here is the mechanism of spironolactone as an aldosterone antagonist leading to potassium retention. The correct answer is hyperkalemia. The incorrect options would be other electrolyte disturbances not associated with spironolactone. For example, hypokalemia is more common with loop or thiazide diuretics, which do not spare potassium. Hypernatremia is unlikely because spironolactone causes sodium excretion. Hyperchloremia might be a distractor, but I'm not sure. The clinical pearl is to remember that potassium-sparing diuretics lead to hyperkalemia and need monitoring.

**Core Concept**
Spironolactone is an **aldosterone antagonist** that inhibits sodium reabsorption and potassium excretion in the distal convoluted tubule. Long-term use leads to **hyperkalemia** due to reduced renal potassium excretion. It is a key side effect in patients with renal impairment or concurrent use of ACE inhibitors/ARBs.

**Why the Correct Answer is Right**
Spironolactone blocks aldosterone receptors, preventing sodium-potassium exchange in the distal nephron. This results in **net sodium excretion and potassium retention**. Hyperkalemia is the most clinically significant metabolic abnormality, as elevated potassium levels can cause arrhythmias and cardiac arrest. Risk factors include reduced renal function, diabetes, or concomitant use of potassium-sparing agents. Monitoring serum potassium is critical during therapy.

**Why Each Wrong Option is Incorrect**
**Option A:** *Hypokalemia* is incorrect

✓ Correct Answer: A. Metabolic acidosis